BioSpace News Archive

ADC Therapeutics SA announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Merck, known as MSD outside of the United States and Canada, announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer whose tumors harbor KRAS G12C mutations and express PD-L1.

Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the launch of a new MyPhenomeTM test that now allows patients to test for all three identified phenotypes - Emotional Hunger, Hungry Gut and Hungry Brain - in one simple test.

UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for BIMZELX®, an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA.

Arbutus Biopharma Corporation today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna.

Citius Pharmaceuticals, Inc. today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024, in New York City.

Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

AngioDynamics, Inc. announced that the United States Food and Drug Administration has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism, enhancing its utility in critical medical scenarios such as PE.